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Circumventing Antivector Immunity:
Potential Use of Nonhuman Adenoviral Vectors
Estrella Lopez-Gordo,1 Iva I. Podgorski,2 Nicholas Downes,3 and Ramon Alemany4
Abstract
Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types
and drive high-level transient transgene expression. While there have been advances in modifying human
adenoviral (HAdV) vectors to increase their safety profile, there are still pitfalls that need to be further
addressed. Preexisting humoral and cellular immunity against common HAdV serotypes limits the efficacy of
gene transfer and duration of transgene expression. As an alternative, nonhuman AdV (NHAdV) vectors can
circumvent neutralizing antibodies against HAdVs in immunized mice and monkeys and in human sera,
suggesting that NHAdV vectors could circumvent preexisting humoral immunity against HAdVs in a clinical
setting. Consequently, there has been an increased interest in developing NHAdV vectors for gene delivery in
humans. In this review, we outline the recent advances and limitations of HAdV vectors for gene therapy and
describe examples of NHAdV vectors focusing on their immunogenicity, tropism, and potential as effective
gene therapy vehicles.
Introduction
Adenoviruses (AdVs) are nonenveloped viruses withan icosahedral capsid containing a double-stranded
linear DNA genome of 26–46 kb (Davison et al., 2003). Since
their discovery in 1950s in human cell cultures (Rowe et al.,
1953), AdVs have been identified in many species, ranging
from fish to humans. Today AdVs form five accepted genera
(Mastadenovirus, Aviadenovirus, Siadenovirus, Atadenovirus,
and Ichtadenovirus) within the family Adenoviridae. Recently,
one more genus was proposed, named Testadenovirus (Dosz-
poly et al., 2013). So far 57 different AdV serotypes (Lukashev
et al., 2008; Walsh et al., 2011) have been isolated from hu-
mans (HAdVs) and are classified within the genus Mastade-
novirus as 7 species, HAdV A through HAdV G (Jones et al.,
2007). While classification was previously based on biological
characteristics (erythrocyte agglutination, oncogenicity, and
by specific antisera neutralization), phylogenetic relation-
ships have been revised and clarified on the basis of genotype
similarity (Bailey and Mautner, 1994; Davison et al., 2003).
Accordingly, individual AdV serotypes frequently share char-
acteristics such as tropism and associated host pathologies with
other serotypes within their species. The tropism is in large part
determined by the capsid proteins that interact with the host
cell surface receptors to mediate cell entry. The capsid consists
primarily of hexon and penton proteins that form pentameric
structures at each of the 12 vertices, securing a trimeric fiber
that projects outward. Other viral proteins include the cement
proteins (IIIa, VI, VIII, and IX) and the core proteins (TP, V,
VII, and mu) that associate with the AdV genome (Vellinga
et al., 2005). While the basic structure of these proteins is
maintained, variations in the length and composition of the
amino acid sequences of these proteins across species and
genera cause them to bind to a number of receptors and host
factors with variable affinity. Thus, the coxsackie and AdV
receptor (CAR), CD46, desmoglein-2 (DSG2), CD80, CD86,
vascular cell adhesion molecule-1 (VCAM-1), heparan
sulfate proteoglycans (HSPGs), major histocompatibility
complex class I-a2 (MHC-I-a2), sialic acid, dipalmitoyl-
phosphatidylcholine, lactoferrin, and others can be utilized
by one or more HAdV serotypes to transduce cells (Sharma
et al., 2009b; Arnberg, 2012).
Viral vectors remain to be the most promising gene
transfer vehicles for gene therapy because of their higher
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gene-transfer efficiencies when compared with other ap-
proaches. Currently, AdV vectors have been used in 23.5%
of all clinical trials as they can efficiently transduce a wide
variety of dividing and quiescent cells, they very rarely in-
tegrate into the host genome minimizing the risk of inser-
tional mutagenesis (Stephen et al., 2010), they have a large
packaging capacity up to 36 kb, and they can routinely be
produced at high titers. Of the 57 HAdV serotypes, HAdV-5
of species C has been the best characterized and the most
widely used in clinical trials so far, mainly in the treatment
of cancer but also as a vaccine (Sullivan et al., 2003; Shiver
and Emini, 2004).
It has, however, been estimated that over 80% of the adult
population have been naturally exposed to the common
HAdV serotypes (Garnett et al., 2002). As a result, pre-
existing humoral and cellular immunity may preclude effi-
cient gene transfer (Kuriyama et al., 1998), and local
systemic immune responses against the vector and transgene
product may result in a number of clinically undesirable
side effects. Severe immune responses against AdV vectors
can have serious consequences in humans, which have been
exemplified by a fatal case of systemic inflammatory re-
sponse syndrome that was directly attributed to the sys-
temically administered AdV gene transfer vector (Raper
et al., 2003). Moreover, upon systemic administration of
recombinant HAdV-5, transduction of immune cells in the
liver and spleen leads to immune responses against the AdV
vector that can limit its therapeutic efficacy. Eliminating
liver tropism and the epitopes involved in viral proteins
recognition by neutralizing antibodies (NAbs) has been
proposed to reduce these immune responses. Taking ad-
vantage of the diversity of AdV capsid protein isoforms and
their variety of ligand–receptor interactions, vectors based
on low seroprevalent AdVs could potentially enable tar-
geting to different cell types as well as overcoming pre-
existing immunity. Naturally, nonhuman AdV (NHAdV)
species have a low seroprevalence in all human populations
and therefore represent a source of potential vectors that
could fit this niche. Since the beginning of their develop-
ment in 1990s (Mittal et al., 1995), recombinant NHAdV
vectors have been derived from many different AdV spe-
cies: canine AdV-2 (CAdV-2), bovine AdV-3 (BAdV-3),
porcine AdV-3 (PAdV-3), ovine AdV-7 (OAdV-7), murine
AdV-1 (MAdV-1), several simian (SAdVs), and fowl
(FAdVs) AdVs. Here we outline the current status of HAdV
vectors, summarize the development of NHAdV vectors,
and discuss the advantages and shortfalls of each.
Innate and Adaptive Immune Responses Against AdVs
Innate and adaptive immune responses play a critical role
in resolving AdV infections. The presence of specific anti-
viral antibodies significantly increases antibody constant
fraction receptor (FcR)-dependent viral internalization in
macrophages, triggering an innate immune response to
AdVs that leads to type I interferon (IFN) production and
caspase-dependent interleukin (IL)-1b maturation (Zaiss
et al., 2009). Internalized AdV DNA induces maturation of
pro-IL-1b in macrophages dependent on NALP3 and ASC,
components of the innate cytosolic molecular complex
called the inflammasome, but independent of Toll-like re-
ceptors (TLRs) and IFN regulatory factors (Muruve et al.,
2008). Later studies reported that this response requires the
binding of the arginine-glycine-aspartic acid (RGD) motif in
the AdV penton base with macrophage b3 integrins (Di
Paolo et al., 2009). Barlan and colleagues also demonstrated
that the specific AdV penetration mechanism of the endo-
somal membranes is required for IL-1b release (Barlan
et al., 2011a,b). Macrophages and conventional dendritic
cells (cDCs) can detect cytosolic AdV DNA in a TLR9-
independent manner (Basner-Tschakarjan et al., 2006; Zhu
et al., 2007), while plasmacytoid DCs (pDCs) detect non-
methylated AdV CpG-containing DNA in the endosomes
through TLR9. Also, internalized HAdV-5 and HAdV-6
immune complexes have been reported to induce DC matu-
ration via TLR9 agonist motifs present in the AdV genome,
whereas HAdV-35, -36, and -26 have a limited potency to
induce DC maturation because of having a smaller number
of motifs (Perreau et al., 2012). TLR9 signaling pathway is
dependent on myeloid differentiation primary response 88
(MyD88) (Yamaguchi et al., 2007; Zhu et al., 2007) and
induces the secretion of IL-6 and IL-12 (Yamaguchi et al.,
2007). Heparin-sensitive receptors on DCs bind to the AdV
shaft fiber region and trigger T cell immune responses (Cheng
et al., 2007). HAdV-5-induced natural killer (NK) cell acti-
vation relies on T cell contribution in vitro (Pahl et al., 2012),
and also appears to be related to the presence of type I IFN
in vivo (Zhu et al., 2007, 2008). In contrast to HAdV-5, in
response to HAdV-35 pDCs alone are sufficient for NK cell
activation in a TLR9-dependent manner, after which NK cells
enhance pDC IFN-a secretion (Pahl et al., 2012). This indi-
cates that both pDCs and T cells may be necessary for NK
cells’ activation. Therefore, it is clear that different AdV se-
rotypes can trigger immune responses in different ways; thus,
it is essential to study immune responses in detail to ensure
that efficient strategies to circumvent immune responses are
developed.
The complement system also plays a critical role in AdV
immune responses with effects mediated through the clas-
sical and alternative complement pathway. The complement
system appears to be related to humoral immune responses
to the vector capsid or the encoded transgene (Appledorn
et al., 2008). IgM isotype neutralization of virions activates
the classical complement pathway hampering receptor–
ligand interactions with the target cell (Xu et al., 2013). On
the other side, AdV-induced thrombocytopenia has been
demonstrated to be dependent on factor B and C3 of the
alternative complement pathway, and AdVs mediate in-
duction of the nuclear factor-kappaB (NF-jB) upon binding
to C3 (Appledorn et al., 2008). In addition to macro-
phages, DCs, and NK cells, binding of the CAR protein and
av-integrins on nonimmune cells also activates immune
responses (Liu et al., 2005; Schoggins et al., 2005). In
particular, CAR-mediated responses have been reported
in epithelial cells (Tamanini et al., 2006) and integrin-
mediated responses in kidney epithelium-derived (REC)
cells, inducing expression of CXCL10 (IP-10) through NF-
jB in an RGD motif-dependent manner (Liu et al., 2005).
These anti-AdV innate immune responses are linked to
adaptive immune responses through direct interactions and
production of cytokines (Ginsberg, 1996; Appledorn et al.,
2008). When a cell is infected by AdVs, it releases type I (a
and b) IFN. Plasmacytoid DCs, cDCs, and macrophages
produce IFN-a upon AdV recognition. The surrounding
286 LOPEZ-GORDO ET AL.
uninfected cells recognize IFN by IFN receptors and they
induce, via the Jak-STAT signaling pathway, the expression
of antiviral enzymes such as MxA, 2¢,5¢-oligoadenylate
synthase, and protein kinase R (Katze et al., 2002). Also,
type I IFN induces upregulation of costimulatory molecules
in DCs such as CD80, CD86, and CD40, leading to DCs’
maturation (Vujanovic et al., 2009). Moreover, IFN takes
part in B cells’ activation for antibody production. Type II
IFN (IFN-c) is an immunoregulatory cytokine secreted by
Th1-type T CD4 + cells, T CD8 + cells, and NK cells. IFN-
c induces the expression of major histocompatibility com-
plex class I (MHC-I) on nearly all cells and major histo-
compatibility complex class II (MHC-II) on professional
antigen presenting cells (APCs) promoting antigen presen-
tation to helper T CD4+ cells, and it also activates macro-
phages (Gattoni et al., 2006).
Dendritic cells have been shown to engulf infected cells
and present antigens to naive T CD8 + cells through MHC-I
(Albert et al., 1998). At the same time, APCs present anti-
gens to Th1-type T CD4 + cells through MHC-II and upon
activation they produce IL-2. If the T CD8 + cell receives
both antigen presence and IL-2 signal, it gets activated
( Jankovic et al., 2001). Once the T CD8 + cell interacts
with an infected cell, mainly recognizing conserved epitopes
in hexon protein (Olive et al., 2002; Leen et al., 2004; Tang
et al., 2006), it begins a cytotoxic response leading to ap-
optosis of the infected cell (Schumacher et al., 2004). On the
other hand, Th2-type T CD4 + cells induce B cell matura-
tion and isotype switching ( Jankovic et al., 2001).
NAbs, mostly IgG isotype, interact with AdV capsid
proteins (Gall et al., 1996; Sumida et al., 2005). It was
reported that NAbs recognize mainly the hypervariable re-
gions (HVRs) of the hexon protein (Roberts et al., 2006;
Abe et al., 2009; Shiratsuchi et al., 2010; Bradley et al.,
2012b) and to a lesser extent the fiber knob domain (Myhre
et al., 2007; Bradley et al., 2012a; Yu et al., 2013) and
penton base proteins (Yu et al., 2013). AdV neutralization
prevents cell attachment and facilitates aggregation and
phagocytosis mediated by opsonization (Wohlfart, 1988).
FcRs in macrophages and NK cells recognize NAbs bound
to AdV antigens, facilitating their phagocytic and cytolytic
action, respectively (Gattoni et al., 2006).
In summary, AdV gene transfer vectors are subjected to
antiviral immune responses (Fig. 1) once administered to the
patient. This process highly limits their efficiency for gene
therapy applications. Therefore, it is critical to understand
the immune response to AdVs and have strategies to cir-
cumvent antiviral immune responses. These will be dis-
cussed in the following sections, focusing on the main
limiting factors: NAbs against AdV proteins and CD8+
cytotoxic T lymphocytes (CTLs) against infected cells.
Implications of Antiviral Immune Responses Against
HAdV Vectors and Strategies to Circumvent Them
Since the tragic death of a patient participating in a
clinical gene therapy trial involving administration of a
replication-incompetent HAdV-5 vector (Raper et al.,
2003), many efforts have been made to avoid antiviral im-
mune responses against AdV vectors to improve their safety
and efficacy. Since the AdV vector recognition by the im-
mune system depends on the existence of antigenic epitopes
in the AdV proteins (i.e., NAbs recognize AdV proteins, and
CD8 + CTLs recognize infected cells), most of the strate-
gies to circumvent the immunogenicity of HAdV vectors are
based on protein modifications.
Functionally significant HAdV-5-specific NAbs are di-
rected primarily against the HAdV-5 hexon protein and to a
lesser extent to fiber and penton base proteins (Gall et al.,
1996; Sumida et al., 2005; Tian et al., 2011). Despite sev-
eral groups successfully generated hexon-chimeric HAdV-5
vectors that partially evaded anti-HAdV-5 immune re-
sponses (Gall et al., 1998; Roy et al., 1998; Ostapchuk and
Hearing, 2001; Wu et al., 2002; Roberts et al., 2006; Bruder
et al., 2012), hexon pseudotyping appears to be a limited
strategy as it has been reported the formation of many
nonviable virions (Youil et al., 2002).
The hexon protein (Rux and Burnett, 2000) contains 7
HVRs (Crawford-Miksza and Schnurr, 1996). Many groups
have exchanged HAdV-5 HVRs with those from low-
prevalent serotypes and demonstrated that the resultant AdV
vector can evade HAdV-5 immunity (Roberts et al., 2006;
Abe et al., 2009; Shiratsuchi et al., 2010). Roberts et al.
(2006) showed that HAdV-5 with all seven HVRs replaced
with the corresponding ones from the rare serotype HAdV-
48 could circumvent HAdV-5 NAbs in both mice and rhesus
monkeys. Further studies (Bradley et al., 2012b) exchanged
only some HVRs and demonstrated that HAdV-5-specific
NAbs target multiple HVRs, suggesting that mutation or
replacement of all seven HVRs would probably be neces-
sary to evade anti-HAdV-5 immunity. However, in 2012,
Coughlan et al. demonstrated that, despite HAdV-5 con-
taining all seven HVRs from HAdV-48, it displayed a de-
creased hepatocyte transduction and accumulation in
Kupffer cells, and it triggered a robust proinflammatory
response not present with the wild-type HAdV-48 (Cough-
lan et al., 2012). In order to generate novel viable HVR-
chimeric vectors able to evade immune responses, it would
be necessary to use HVRs from other serotypes, and for that
it is essential to determine the viability of HVR replace-
ments in AdV vectors based on the structural and bio-
chemical constraints of the different HVRs that limit their
manipulation.
Regarding the immunogenicity of the fiber protein, little
is known about the epitopes involved in fiber recognition by
NAbs, although it is thought that antiknob NAbs represent
the major population of antifiber NAbs (Myhre et al., 2007;
Bradley et al., 2012a; Yu et al., 2013). It has been reported
that fiber pseudotyping of AdV vectors can lead to reduced
AdV-associated innate (Schoggins et al., 2005) and adaptive
immune responses (Parker et al., 2009; Roge´e et al., 2010).
Despite the C-terminal and shaft region heterogeneity, the
N-terminal region (fiber tail) that is bound to penton base
protein presents high similarity among diverse AdV species
(Tarassishin et al., 2000). Thus, designing chimeric AdV
vectors containing all proteins from HAdV-5 but fibers from
other serotypes (mainly species B and D) is a very inter-
esting approach to retarget HAdV-5 to different tissues
while circumventing antiviral preexisting immunity. Thus,
several chimeric AdV vectors with tropism for different cell
types such as HAdV-5/3 (Haviv et al., 2002; Kanerva et al.,
2002; Volk et al., 2003; Ulasov et al., 2007), HAdV-5/11
(Havenga et al., 2001; Stone et al., 2005; Wang et al.,
2011b), HAdV-5/16 (Havenga et al., 2001), and HAdV-5/35
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(Havenga et al., 2001) were generated. Interestingly, HAdV-
5/35 and -5/11 were assessed in vivo in murine and non-
human primate animal models, showing reduced toxicity
and limited induction of inflammatory cytokines (Ni et al.,
2005). However, other studies showed that HAdV-5/35
presented tropism for CD34 + human hematopoietic stem
cells in vitro (Shayakhmetov et al., 2000), monocytes,
granulocytes, and blast cells of human bone marrow (Ro-
gozhin et al., 2011), and CD4 + and CD8 + T lymphocytes
in vitro (Zhang et al., 2013b). Since transduction of immune
cells can lead to immune responses, extensive character-
ization of chimeric AdV vectors is essential.
Other retargeting strategies such as the truncation or re-
moval of the fiber knob domain and its replacement with
foreign trimerization motifs and heterologous peptides fused
to the fiber shaft are also recently being assessed (fiber de-
knobbing) (Coughlan et al., 2010). Despite that the removal
of the fiber knob domain results in a lower number of fiber
copies per virion, leading to a less efficient production of the
AdV vector, it has been shown that this approach may
contribute to evade NAbs (Myhre et al., 2007).
Regarding the adaptive immunity mediated by CD8+
CTLs, the response depends on viral antigenic epitopes
loaded in the MHC of the infected cell. High-capacity,
helper-dependent (HD) vectors (also called gutless vectors)
bypass this problem (Kochanek et al., 1996) as they are
devoid of all viral genes, and therefore they are less im-
munogenic and allow long-term transgene expression
(Maione et al., 2001; Ehrhardt and Kay, 2002; Dudley et al.,
2004). Furthermore, as in these vectors DNA is constituted
of stuffer DNA as part of the vector backbone to maintain
optimum vector size, nonmethylated viral CpG-containing
FIG. 1. Innate and adaptive antiadenoviral immune responses. (1) Activation of macrophages and natural killer (NK) cells
by recognition of opsonized adenovirus (AdV) through antibody-constant fraction receptor (FcR). (2) Interleukin (IL)-1b
maturation upon binding of arginine-glycine-aspartic acid (RGD) motif in the AdV penton base with macrophage b3
integrins. (3) Induction of IL-6 and IL-12 secretion in plasmacytoid dendritic cell (pDC) upon AdV DNA recognition
through Toll-like receptor (TLR)-9. (4) Dendritic cell (DC) maturation through internalized immune complexes (ICs). (5)
Triggering of T cell immune responses upon binding of AdV fiber shaft region to heparin-sensitive receptors on DCs. (6)
Interferon (IFN)-a production by activated pDCs, conventional DCs (cDCs), and macrophage and IFN-a recognition by
uninfected cells leading to a cellular antiviral state. (7) Induction of CXCL10 expression by AdV penton base RGD motif
binding to av integrins. (8) Secretion of IFN-a and b by infected cells. (9) Classical complement pathway activation by
virion neutralization with IgM or recognition by IgG. (10) Thrombocytopenia related to alternative complement pathway
activation on AdVs. (11) Major histocompatibility complex class II (MHC-II) induction on professional antigen presenting
cells (APCs) by IFN-c signal promoting antigen presentation to helper T CD4 + cells. (12) Induction of B cell maturation
and isotype switching through AdV antigen presentation by Th2-type T CD4 + cells. (13) Activation of T CD8 + cells
through AdV antigen presentation by DC via MHC-I. (14) IL-2 production by Th1-type T CD4 + cells upon AdV antigen
presentation by APCs through MHC-II, which activates T CD8 + cells. BCR, B cell receptor; C3b, complement component
3b; CAR, coxsackie virus and adenovirus receptor; IFN R, interferon receptor; TCR, T cell receptor.
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DNA (recognized by DCs through TLR9) can be eliminated.
However, one study showed that HD AdVs also trigger an
innate immune response dependent on TLR9 (Cerullo et al.,
2007). Despite the advantages they offer, HD vectors are
equally neutralized by preexisting antibodies against capsid
proteins and also may present transgene-encoded protein
immunogenicity (Tripathy et al., 1996).
On the other hand, the activation of immune responses
because of interactions between AdV capsid proteins and
receptors in the target cell can limit AdV vector efficacy in
gene therapy applications. HAdV-5 binds to the CAR pro-
tein on human erythrocytes in the bloodstream, limiting its
delivery to the in vivo target tissue and contributing to
toxicity (Seiradake et al., 2009). To avoid this interaction,
Nicol et al. (2004) described two CAR-binding mutations
that abolished the previously described agglutination in
human and rat erythrocytes. Moreover, HAdV-5 binding to
CAR activates immune responses that can limit its potential
as a gene transfer vector (Schoggins et al., 2005; Tamanini
et al., 2006). Other interactions such as RGD with macro-
phage b3 integrins (Cheng et al., 2007; Di Paolo et al.,
2009) or the one between the shaft fiber region and the
heparin-sensitive receptor from DCs (Cheng et al., 2007)
have also been associated with immune responses and, in
the case of RGD motif, through IL-1a production (Di Paolo
et al., 2009). Interestingly, the mutation of the RGD motif to
arginine-glycine-glutamic acid (RGE) resulted in a signifi-
cant fivefold reduction in spleen uptake, diminishing the
antiviral inflammatory response after intravascular admin-
istration (Bradshaw et al., 2012). These studies indicate that
de-targeting from native receptors could be a useful ap-
proach to avoid immune responses against the AdV vector.
Nevertheless, further research needs to be done to describe
the pathways through which the AdV vectors trigger im-
mune responses. There are more factors involved in cellular
recognition that could also be implicated in promotion of
immune responses. These include alternative receptors and
coreceptors such as FcR (Xu et al., 2008), complement-3
receptor (CR-3) (Xu et al., 2008), HSPGs and low-density
lipoprotein receptor-related protein (LRP) (Shayakhmetov
et al., 2005), complement receptor-1 (CR1) (Carlisle et al.,
2009), scavenging receptor-A (SR-A) (Khare et al., 2012),
bridging molecules such as the coagulation factor IX, X, and
VII and protein C (Parker et al., 2006), complement com-
ponent C4-binding protein (C4BP) (Shayakhmetov et al.,
2005), and IgM antibodies (Xu et al., 2008). Further studies
will have to be done in order to describe their influence on
the use of HAdV vectors for gene therapy applications.
Apart from genetic engineering of HAdV vectors, other
strategies such as chemical modifications by addition of cat-
ionic polymers or lipid molecules to shield AdV vectors and
prevent them from binding undesired proteins have been
widely studied. Several variants of polyethylene glycol (PEG)
have been used, but better shielding was found with multiva-
lent copolymers of poly[N-(2-hydroxypropyl)methacrylamide]
(pHPMA). Shielding of HAdV vectors with pHPMA showed
an increased biological stability of the vector and a longer
persistence in blood, decreased liver transduction, and there-
fore a lower immune response (Green et al., 2004). Further-
more, coated HAdV vectors have been shown to be less
vulnerable to recognition by preexisting NAbs in vitro (Ro-
manczuk et al., 1999; Wang et al., 2011a) and by Kupffer cells
in the liver (Mok et al., 2005), likely because of the hampered
interaction of PEGylated AdVs and Kupffer cell SR-A
(Haisma et al., 2009). However, other factors could be af-
fecting liver transduction of the coated HAdV such as the
limited size of the sinusoidal endothelial cells’ fenestrae
(Hofherr et al., 2008). The use of PEGylated HAdV vectors
resulted in decreased levels of IL-6 production in vitro (Mok
et al., 2005) and of IL-6 and IL-12 in vivo (Croyle et al.,
2000). Moreover, coated HAdV vectors induce lower IL-6
levels in serum because of decreased levels of spleen AdV
uptake (De Geest et al., 2005). Furthermore, several groups
successfully retargeted coated AdV vectors (Parker et al.,
2005; Stevenson et al., 2007; Morrison et al., 2008, 2009;
Wang et al., 2010). Although in some studies they presented
similar levels of antitumoral efficacy (Morrison et al., 2009) or
transgene expression (Parker et al., 2005; Stevenson et al.,
2007; Morrison et al., 2008; Wang et al., 2010) to unmodified
wild-type HAdV-5, others achieved a greater therapeutic effect
with negligible side effects (Eto et al., 2010; Yao et al., 2010).
Despite the limited retargeting efficiency in comparison with
unmodified HAdV-5, the use of PEGylated AdV vectors
achieved lower hepatic tropism and reduction in liver and
spleen toxicity in vivo. Moreover, evidence highlights the
potential of AdV polymer coating strategies to circumvent
preexisting immunity to all viral capsid proteins (Romanczuk
et al., 1999; Croyle et al., 2000; De Geest et al., 2005; Mok
et al., 2005; Haisma et al., 2009; Zeng et al., 2012). Never-
theless, the reported PEG immunogenicity could hamper PE-
Gylated AdVs efficacy (Shimizu et al., 2012).
Despite the advances made in HAdV vectors to evade
anti-AdV immune responses, the current strategies are
limited by the formation of nonviable virions following
molecular engineering and by the limited knowledge and
characterization of capsid epitopes motifs responsible for
cross-reactivity. Therefore, the use of low-seroprevalent
HAdV serotypes has been proposed as an alternative to
hexon or fiber-chimeric AdV vectors in order to circumvent
preexisting NAbs. More than 15 years ago, several studies
showed that the alternate use of AdV vectors from different
serotypes, even within the same AdV species, can circum-
vent anti-AdV humoral immunity (Kass-Eisler et al., 1996;
Mastrangeli et al., 1996; Mack et al., 1997; Parks et al.,
1999). A study on the presence of NAbs against different
HAdV serotypes in the Belgian population reported high
seroprevalence toward species A, C, and E, while low sero-
prevalence toward species B and D, among which, serotypes
11, 34, 35, 50 (species B), 43, and 48 (species D) showed the
lowest values (Vogels et al., 2003). This indicates that these
serotypes could be potentially used to evade preexisting
immunity. Vectors have been developed from multiple
HAdV serotypes with lower seroprevalence than HAdV-5:
HAdV-11 (Holterman et al., 2004; Stone et al., 2005; Ab-
bink et al., 2007), HAdV-35 (Gao et al., 2003; Sakurai
et al., 2003, 2009; Seshidhar Reddy et al., 2003; Vogels
et al., 2003; Barouch et al., 2004; Wu and Tikoo, 2004;
Abbink et al., 2007; Brouwer et al., 2007; Sakurai, 2008;
McVey et al., 2010; Geisbert et al., 2011), HAdV-49
(Lemckert et al., 2006; Abbink et al., 2007), HAdV-26, -48,
and -50 (Abbink et al., 2007; Geisbert et al., 2011), HAdV-7
(Nan et al., 2003), and HAdV-6 (Capone et al., 2006).
However, since the presence of NAbs depends on AdV
exposure, which is closely related to geographical location,
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seroprevalence studies in different specific populations are
very important. Moreover, better characterization of such
serotypes in terms of tropism and specificity, biodistribution,
and toxicity is yet required to design safe HAdV vectors.
Use of Nonhuman Adenoviral Vectors
The idea about NHAdVs as vectors appeared in 1990s,
with the assumption that they would be more useful for
vaccines and gene therapeutic approaches in human medi-
cine than HAdV-based vectors. Design and characterization
of NHAdV vectors was reviewed earlier (Bangari and
Mittal, 2006), with a focus on vaccine vectors. In this review
we focus on the progress in the development of NHAdV
vectors (Table 1) for gene therapy.
Canine AdV vectors
Canine AdV (genus Mastadenovirus, species CAdV A)-
derived vectors are currently the best described NHAdV
vectors. Up to 90% of the residues involved in CAdV-2 fiber
tail-penton base interactions are conserved compared with
HAdV-5 (Schoehn et al., 2008). CAdV-2 binds to CAR
(Tomko et al., 1997; Soudais et al., 2000), but it does not
contain an integrin-interacting RGD motif in the penton base
(Chillon and Kremer, 2001) in contrast with HAdV-5 (Greber,
2002). CAdV-2 penton base appears to be*20% shorter than
that of HAdV-5 (Schoehn et al., 2008). In addition, CAdV-2
has shorter protuberances on the top of the penton base,
mainly where RGD motif is contained in HAdVs, and a
shorter N-terminal region. The hypervariable loops in the
hexon protein are shorter in CAdV-2 and the protruding
structures containing the epitopes recognized by antihexon
HAdV-5 antibodies are absent, while the fiber is more com-
plex since the shaft region contains two bends (Schoehn et al.,
2008). Also, protein IX and IIIa are shorter in CAdV-2
(Schoehn et al., 2008). Production of CAdV-2 vectors started
more than 15 years ago (Klonjkowski et al., 1997) in an at-
tempt to avoid the inhibitory effect of the preexisting humoral
and cellular immunity against HAdVs when used in the clinics.
Later, it was shown that CAdV-2 vectors rarely cause neither
the activation and proliferation of T cells nor the maturation of
DCs (Perreau and Kremer, 2006). The advantage of these
vectors over HAdV vectors is that CAdV-2 mainly interacts
with CAR (Soudais et al., 2000) and they present specific
tropism for neurons in the central nervous system (Soudais
et al., 2001) with great capacity for axonal transport in vivo.
Taking into account that CAdV-2 vector development was
recently reviewed (Bru et al., 2010), the following data will
focus on the more recent trials performed with the mentioned
vector. Until very recently, the production of CAdV-2 vectors
was based on dog kidney (DK) cell lines (Kremer et al., 2000),
which is not accepted by the Food and Drug Administration
(FDA) and the European Medicine Agency (EMA). To cir-
cumvent this problem, CAdV-2 E1-transcomplementing cell
lines, based on Madin-Darby canine kidney (MDCK) cells
accepted by the FDA and EMA for the production of vaccines,
have been developed (Fernandes et al., 2013a). CAdV-2 vector
DNA replication in the MDCK-E1 cell line was shown to
correlate with the expression levels of the transcomplementing
E1A and E1B. While Cre recombinase expression in MDCK-
E1-Cre cell lines (for HD CAdV-2 vectors production) can
impair cell growth, controlled expression of Cre was deter-
mined not to result in negative effects on viral production
(Fernandes et al., 2013b). CAdV-2-based vectors are ideally
suited for treating neurological disorders, but because of vector
titer limitations, large volumes are necessary for applicability
in the clinics. Therefore, better purification and scalable pro-
duction according to good manufacturing practice (GMP) are
being currently developed (Segura et al., 2012; Fernandes
et al., 2013a), and the improvement of producer cell lines has
increased vector titers (Ibanes and Kremer, 2013). In a com-
parative study on HD HAdV, HD CAdV-2, and a VSV-G
lentiviral vector, the transduction efficiency and transgene
expression in human midbrain neuroprogenitor cells was as-
sessed. HD CAdV-2 was determined to have the most prom-
ising vector profile: equal transduction efficacy, no negative
effect to neuronal development, and milder induced immune
response (Piersanti et al., 2013). HD CAdV-2 was also used
as a vector in order to evaluate a gene therapy approach to
correct the neurodegenerative lysosomal storage disorder
mucopolysaccharidosis type IIIa (Lau et al., 2012). It was
shown to effectively transduce neurons and provide long-term
transgene expression; however, its use in vivo was limited to
discrete areas of the brain, indicating a need to find a way to
increase transgene expression throughout the whole brain.
Furthermore, in a clinically relevant stroke model in rats,
cortical CAdV-2 vector injection transduced neurons at a
greater level and covered a larger region than lentiviral
vectors (Ord et al., 2013), reducing infarct volume and im-
proving neurologic recovery. For all the potential of CAdV-2
vectors, there ultimately remains the need for further under-
standing of the effects of CAdV-2 vectors on human cells
before they are able to enter human clinical trials.
Bovine AdV vectors
Bovine AdVs (genus Mastadenovirus, species BAdV A,
B, C; genus Atadenovirus, species BAdV D) were the first
Table 1. Most Popular Nonhuman Adenovirus
Used as a Vector
Species Genus Serotype
Canine adenovirus A Mastadenovirus CAdV-2
Bovine adenovirus B Mastadenovirus BAdV-3
Porcine adenovirus A Mastadenovirus PAdV-3
Human adenovirus E Mastadenovirus ChAdV-68/Pan
9/SAdV-25
ChAdV-5/Pan
5/SAdV-22
ChAdV-6/Pan
6/SAdV-23
ChAdV-7/Pan
7/SAdV-24
Human adenovirus G Mastadenovirus SAdV-7
Murine adenovirus A Mastadenovirus MAdV-1
Fowl adenovirus A Aviadenovirus FAdV-1
Fowl adenovirus C Aviadenovirus FAdV-10
Fowl adenovirus D Aviadenovirus FAdV-9
Fowl adenovirus E Aviadenovirus FAdV-8
Ovine adenovirus D Atadenovirus OAdV-7
Different species of nonhuman adenovirus are listed, specifying
the genus to which they belong and the serotypes from which the
vectors have been constructed.
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NHAdVs used for vectoring purposes. Mittal and colleagues
substituted the nonessential E3 region of BAdV-3 (BAdV B
species) with the firefly luciferase reporter gene, and lucif-
erase expression lasted at least 6 days postinfection in
human embryonic kidney (HEK)-293 cells (Mittal et al.,
1995). BAdV-3 might be a better option to target a specific
tissue or organ, since its cell entry is independent of CAR
(Bangari et al., 2005b) and other primary receptors of
HAdV-5 (Bangari et al., 2005a). BAdV-3 uses sialic acid
molecules as a primary receptor to enter into host cells (Li
et al., 2009) and it can efficiently transduce different cell
types of various species. However, it shows limitations in
transducing human cell lines (Rasmussen et al., 1999; Wu
and Tikoo, 2004; Bangari et al., 2005b). To circumvent this
problem, capsid proteins (fiber and pIX) were genetically
modified to increase the ability of BAdV-3 to transduce
nonbovine cells (Zakhartchouk et al., 2007). Studies on
BAdV-3 vectors in vivo biodistribution in a mouse model
showed efficient transduction of the heart, kidney, and lung
in addition to liver and spleen with a longer duration and
higher levels of transgene expression than HAdV-5 vectors
(Sharma et al., 2009a). In a mouse model of breast cancer,
the biodistribution of BAdV-3 vector was comparable to
that of HAdV-5 vectors, the vector had the ability to effi-
ciently transduce tumor and systemic tissues in the presence
of HAdV-5 immunity, and it evaded sequestration by
Kupffer cells (Tandon et al., 2012). Also, it has been shown
that there is minimal cross-neutralization by preexisting
anti-HAdV immunity in humans (Bangari et al., 2005b).
These results show the suitability of BAdV-3 vectors as a
delivery system for cancer gene therapy while circumvent-
ing preexisting antivector immunity. Moreover, BAdV-3
and HAdV-5 vectors have a comparable biological behavior
in human, bovine, porcine, and mouse cell lines and both
genomes persist at high levels in vector-permissive cell lines
in the absence of immune pressure, proving BAdV-3 vec-
tors’ safety for their use as gene delivery vehicles (Sharma
et al., 2011).
Porcine AdV vectors
The idea of using PAdV (genus Mastadenovirus, species
Porcine A, B, C) vectors was published over 20 years ago
(Tuboly et al., 1993). A few years later it was discovered that
the virus can enter but is unable to replicate in dog, sheep,
bovine, and human cells (Reddy et al., 1999a). Soon after,
PAdV-3 (PAdV A species) vectors were constructed with the
long-term objective to develop replication-competent PAdV-3
as a live gene transfer vector to induce a mucosal immune
response in pigs (Reddy et al., 1999b). Recombinant PAdV-3
is an effective delivery system in pigs (Hammond and Johnson,
2005), and it is often studied together with BAdV-3 vectors,
showing similar properties: lack of cross-neutralization
with preexisting anti-HAdV immunity in humans (Bangari and
Mittal, 2004; Bangari et al., 2005b), CAR- and integrin-
independent cell entry (Bangari and Mittal, 2005; Bangari
et al., 2005b), similar safety profile and biological character-
istics (Sharma et al., 2011), efficient transduction of several
cell types of various species with PAdV-3 having an advantage
in specific targeting of the breast tissue (Bangari et al., 2005b),
and the vector genomes remain as linear episomes (Sharma
et al., 2009a). In contrast with BAdV-3 vectors, the genome
levels of PAdV-3 vector were shown to be comparable or
lower than those of HAdV-5 vectors in vivo in a mouse model,
except in the case of the heart, where the levels were compa-
rable or higher (Sharma et al., 2009a). The specificity of PAdV
vectors for distinct tissues is very interesting for the design of
vectors for targeted gene delivery.
Simian AdV vectors
Simian AdVs are grouped into several human (certain
HAdV species contain simian or ape AdVs, based on species-
demarcation criteria such as phylogenetic distance and nu-
cleotide composition) and simian AdV species within the
genus Mastadenovirus. The first gene transfer vector derived
from chimpanzee AdV-68 (ChAdV-68/Pan 9/SAdV-
25; species HAdV E) was able to grow in HEK293-
complementing cells without being neutralized by antibodies
against HAdV serotypes (Farina et al., 2001). Since neutral-
izing seroprevalence to ChAdV-68 in different regions of the
world is significantly lower than that to HAdV-5 (Xiang
et al., 2006; Ersching et al., 2010; Zhang et al., 2013a), that
makes it a good candidate for application in humans. Inter-
estingly, a single surface loop defines a major neutralization
site for the ChAdV-68 hexon (Pichla-Gollon et al., 2007),
which when mutated, permitted the virus to escape from
neutralization by polyclonal antisera obtained from animals
in vitro. This was actually the first neutralizing site identified
for any AdV, which was later very important for the suc-
cessful application of the vectors in the clinics. Gene delivery
by ChAdV-68 is CAR dependent (Cohen et al., 2002), and
unlike the E1 of HAdV-5, the flanking sequences of ChAdV-
68 are nonhomologous with cell-derived E1, preventing the
formation of replication-competent viruses (Xiang et al., 2002).
Development of vectors derived from chimpanzee AdVs Pan 5
(ChAdV-5/SAdV-22), Pan 6 (ChAdV-6/SAdV-23), and Pan 7
(ChAdV-7/SAdV-24), members of HAdV E species, started in
2004 (Roy et al., 2004). The vectors transduced skeletal muscle
with the same efficiency as HAdV-5 vectors, but without being
neutralized by human sera, and the neutralization domains
showed to be different in Pan 6 and Pan 7 both in vitro and
in vivo.
One study investigated the importance of neutralizing
determinants on capsid proteins by using chimeric vectors
with different combinations of Pan 7 and Pan 6 penton base,
and hexon and fiber proteins (Roy et al., 2005), reporting
that both hexon and fiber have neutralization epitopes and
that in vivo transduction was more affected by antihexon
antibodies, with no effect of antipenton base NAbs. Other
studies on seroprevalence rates of various ChAdVs were
carried out, with Pan 6 and Pan 7 seeming promising as
gene therapy vectors although depending on the region where
the potential patients live ( Jian et al., 2013). A tropism-
modified derivative of Pan 7 showed several advantages over
HAdV-5 for the use in gene therapy: lower degree of in-
activation, diminished liver transduction caused by poor
stability of FX-Pan 7 complexes, greater gene delivery effi-
ciency than the wild-type control Pan 7 vector in vitro, and
higher transduction in vivo of the Her2 (human epidermal
growth factor receptor type 2)-expressing human tumor cells
injected intravenously in mice but not statistically significant
compared with the control (Belousova et al., 2010). The last
finding indicates that there is a need to improve the vector to
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achieve the desired levels of target-specific transduction. Pan
6 vector demonstrated a better capacity than HAdV-5 vector
in transduction of brain tumor cells and glioma cells, indi-
cating that it is a promising vector candidate for the brain
tumor therapy (Skog et al., 2007). Twenty E1-deleted vectors
were generated from different AdVs isolated from chimpan-
zees, bonobos, and gorillas, of which 12 could be propagated,
rescued, and expanded in HEK293 cells (Roy et al., 2011b).
SAdV-7 (HAdV G species) was proposed for vectoring a few
years earlier (Purkayastha et al., 2005b), and was subse-
quently constructed as an E1-deleted vector that could be
complemented by HAdV-5 E1 genes in HEK293 cells (Roy
et al., 2011a). The latter observation was surprising since
SAdVs from HAdV G species are phylogenetically quite
distant from HAdV C members.
Recently, it was shown that humans have low seroreactivity
against simian-derived (SAdV-11, -16) or chimpanzee-
derived (ChAdV-3, -63) AdV vectors compared with HAdV
vectors (rHAdV-5, -28, -35) across multiple geographic re-
gions (Quinn et al., 2013). Chimpanzees and macaques eli-
cited a systemic humoral but not systemic cellular immune
response to endogenous AdVs. The structure of the E3 locus,
involved in modulating the host’s response to infection, is
smaller in HAdVs than in ape AdVs, which may impact the
ability of the ape AdVs to evade host immune detection and
elimination (Calcedo et al., 2009). ChAdV-68 showed the
ability to transduce immature and mature human DCs, fol-
lowed by secretion of IFN-a and IL-6 but not IL-12 or tumor
necrosis factor (TNF)-a, and transduced immature DCs could
stimulate proliferation of autologous T lymphocytes (Var-
navski et al., 2003). Therefore, ChAdV-68 could be used as a
vector for transduction of human DCs.
Fowl AdV vectors
Construction of FAdV (genus Aviadenovirus, species
FAdV A to FAdV E) vectors started with the demonstration
that recombinant FAdV-10 (FAdV C species) could be used
to express an antigen to induce a protective immune re-
sponse in pathogen-free chickens (Sheppard et al., 1998).
After the identification of FAdV-9 (species FAdV D) re-
gions that are nonessential for the virus (Ojkic and Nagy,
2001, 2003; Corredor and Nagy, 2010a), FAdV-9 recom-
binants demonstrated wild-type growth kinetics, virus titers,
cytopathic effect and plaque morphology (Corredor and
Nagy, 2010a), expression in avian and mammalian cells,
and lack of replication in mammalian cells, indicating their
applicability as gene delivery vehicles for mammalian sys-
tems (Corredor and Nagy, 2010b). FAdV-8 (species FAdV
E) vectors were also constructed and showed efficacious
in vivo delivery of antibody fragments against pathogenic
infectious bursal disease virus (Greenall et al., 2010).
FAdV-1 (species FAdV A) or CELO (Chicken Embryo
Lethal Orphan) vectors have been widely used. The geno-
mic regions that could be deleted were evaluated more than
10 years ago and a cosmid-based strategy was developed for
generating CELO vectors (Michou et al., 1999; Franc¸ois
et al., 2001). FAdV-1 has several interesting properties: it
interacts with CAR and its capsid architecture allows
changes in its tropism (Tan et al., 2001), it transduces
mammalian cells as efficiently as HAdV-5 vector, and it has
a potential for mammalian gene transfer applications, es-
pecially because it has larger DNA packaging capacity and
greater physical stability (Michou et al., 1999). It was
shown that FAdV-1 is able to deliver p53 transgene into
various tissues in vivo restoring p53 function in human
tumor cell xenografts in mice and leading therefore to the
inhibition of tumor growth (Logunov et al., 2004). More-
over, FAdV-1 encoding the human IL-2 gene can success-
fully produce biologically active recombinant IL-2 in vitro,
in ovo, and in vivo, and it is capable of increasing the me-
dian survival time of mice carrying melanoma tumors
(Shmarov et al., 2002; Cherenova et al., 2004). Also, re-
combinant FAdV-1 encoding the HSV-1 thymidine kinase
showed cytotoxicity in carcinoma cell lines and suppressed
tumor growth and increase median of survival of mice with
melanoma tumors (Shashkova et al., 2005), demonstrating
its efficacy for the gene delivery to tumor cells in vitro and
in vivo. Furthermore, one study showed that FAdV-1 suc-
cessfully enhanced expression levels of secreted alkaline
phosphatase reporter gene in transduced mammalian cells
in vitro and in vivo (Tutykhina et al., 2008). Finally, PE-
Gylated and retargeted with fibroblast growth factor, FAdV-
1 showed increased levels of binding and internalization in a
variety of human cell lines (Stevenson et al., 2006), with
transgene expression being greater than the unmodified
version in PC-3 human prostate cells, and being fully re-
sistant to inhibition by human serum in vitro (Stevenson
et al., 2006). All together indicates that retargeting of CELO
virus to human cells via disease-specific receptors is possi-
ble, while avoiding preexisting humoral immunity.
Ovine AdV vectors
The production of OAdV (genus Mastadenovirus, species
OAdV A, B; genus Atadenovirus, species OAdV D) vectors
started more than 15 years ago (Xu et al., 1997) after de-
termining the nonessential regions within the genome (Vrati
et al., 1996). Surprisingly, much larger insertions than ex-
pected are tolerated, and portions of sequences can be de-
leted without affecting virus viability (Xu et al., 1997). The
primary receptor for OAdV-7 (OAdV D species) is not
CAR, as it was shown that OAdV-7 does not compete with
HAdV-5 for the entry into cells (Xu and Both, 1998; Voeks
et al., 2002). Recombinant OAdVs can infect a variety of
nonovine cells such as rabbit, human, and murine cells but
cannot replicate within them (Khatri et al., 1997; Hofmann
et al., 1999; Lo¨ser et al., 2000; Xu et al., 2000; Ku¨min et al.,
2002; Lockett and Both, 2002). They are not neutralized by
polyclonal serum against HAdV-5 (Xu and Both, 1998) and
they can overcome preexisting humoral immunity against
HAdVs in vivo (Hofmann et al., 1999). A cosmid-based
system proved useful for efficient generation of recombinant
OAdVs and vectors could be rescued in an ovine fetal skin
fibroblastic producer cell line (Lo¨ser et al., 2003). OAdV-7
carrying purine nucleoside phosphorylase (PNP), which
converts the prodrug fludarabine into its activated form 2-
fluoroadenine, was effective in vivo against prostate cancer
progression upon prodrug addition (Voeks et al., 2002;
Martiniello-Wilks et al., 2004). Moreover, recombinant
OAdV-7 expressing ovalbumin showed efficacy in inducing
antitumor response in a mouse model (Tang et al., 2012).
OAdVs’ biosafety profile and their application as gene de-
livery vectors were reviewed in the last decade (Both, 2004).
292 LOPEZ-GORDO ET AL.
Murine AdV vectors
The production of MAdV (genusMastadenovirus, species
Murine A, B, C) mutants started with the MAdV-1 (MAdV
A species) E3-deleted recombinant (Beard and Spindler,
1996; Cauthen et al., 1999) and E1-deleted recombinant
(Ying et al., 1998). MAdV-1 presents mouse endothelial cell
tropism (Charles et al., 1998; Kajon et al., 1998; Lenaerts
et al., 2005), but it can also infect human endothelial cells
(Nguyen et al., 1999) and it displays higher affinity for
primary human smooth muscle cells than recombinant
HAdV-5 (Lenaerts et al., 2009). MAdV-1 lacks the RGD
motif in the penton base, but it contains it in the fiber knob
domain (Raman et al., 2009). The RGD motif was reported
to play a role in MAdV-1 infection through av integrins,
which act as a receptor for the virus, and it was shown that
cell surface heparan sulfate glycosaminoglycans are in-
volved in MAdV-1 infection (Raman et al., 2009). Con-
versely, the primary attachment of MAdV-1 is independent
of CAR (Lenaerts et al., 2006). Distribution of MAdV-1 to
the liver is markedly lower in intravenously injected im-
munodeficient mice than that observed with recombinant
HAdV-5 (Lenaerts et al., 2009). Moreover, MAdV-1 has
been used as an oncolytic vector, proving that it is a suitable
murine homolog model to test the mechanism of action of
murine oncolytic AdV vectors in an immunocompetent,
tumor-bearing host (Robinson et al., 2009). Furthermore,
MAdV-1 has preference for ovarian carcinoma cell lines,
probably because of their increased expression of the en-
zyme involved in HSPG biosynthesis, therefore having the
potential to be used in the oncolytic treatment of ovarian
cancer (Lenaerts et al., 2012).
Concluding Remarks and Future Perspectives
The main limitation of clinically applied HAdV-based
vectors today is their failure in achieving high levels of ef-
ficient transduction in their target tissues. This is primarily
because of the preexisting NAbs leading to the rapid clear-
ance of circulating vector and cellular immune responses
resulting in the elimination of transduced cells, greatly lim-
iting the expression of the transgene. These immunological
responses most likely stem from the high frequency of HAdV
exposure in multiple human populations across the globe,
which results in immunological memory against HAdV sero-
types that most of today’s vectors are based on. In order to
circumvent this, several strategies have been developed for
HAdVs, including molecular engineering of chimeric vectors
or the use of low-seroprevalent HAdV vectors.
As an alternative, NHAdV vectors have been developed
and are being tested in various nonhuman and human cell
lines. Most of the NHAdV vectors have two important
features that make them more appropriate than HAdV
vectors: there is no or very low pathogenicity for their
natural host, and there is no presence of preexisting NAbs,
CD4+ T cells, and CD8 + CTLs against them. However, it
should be noted that caution must be applied when using
nonhuman primate AdVs, since their ability to infect human
cells and their structural similarity could potentially result
in anti-HAdV T-cell and/or NAb cross-reactivity with non-
human primate AdV antigens. Different NHAdVs have
specific tropism for different cell types, which makes them
applicable in treating different diseases especially when the
targeting of specific cells is required, and therefore they
could extend the range of potential target tissues. Further-
more, the inability of NHAdVs to co-replicate with wt
HAdVs, as well as the fact that they are replication defective
in human cells, makes their vectors much safer than HAdV
vectors. Many of the NHAdVs are able to tolerate longer
sequences of exogenous DNA than HAdVs. For some of the
NHAdVs, there are low-cost propagation systems available,
for example, chicken embryos for CELO virus (Laver et al.,
1971; Michou et al., 1999). Despite these advantages, there
are still many steps necessary before using the NHAdV
vectors in the clinics. The first challenge is to find the ap-
propriate cell lines for efficient production. There are also
safety issues compared with HAdVs such as the possible
occurrance of interspecies adaptation. For example, HAdV-
4 is the only HAdV member of HAdV E species that is very
similar to SAdVs from that group, indicating its zoonotic
origin and molecular adaptation to its new host (Purkayastha
et al., 2005a; Dehghan et al., 2013). As AdVs have co-
evolved with their hosts (Benko¨ and Harrach, 2003; Davison
et al., 2003), there is a possibility that humans and monkeys
could be infected with the same AdVs, a concern when
considering chimpanzee or simian AdV vectors for use in
humans. Nevertheless, NHAdV vectors present great po-
tential as effective gene therapy vehicles and will hopefully
be part of the successful AdV vectors used in the clinics in
the coming years.
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